194 related articles for article (PubMed ID: 9619746)
1. 5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study.
Palmeri S; Meli M; Danova M; Bernardo G; Leonardi V; Dastoli G; Rausa L; Russo A; Filippelli G; Palmieri G; Russo A; Della Vittoria Scarpati M; Lo Russo V; Di Lauro L; Colucci G; Bruni G; Piazzi M; Gebbia N; Spada S
J Cancer Res Clin Oncol; 1998; 124(3-4):191-8. PubMed ID: 9619746
[TBL] [Abstract][Full Text] [Related]
2. 5-Fluorouracil versus 5-fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma. A randomized study.
Dufour P; Husseini F; Dreyfus B; Cure H; Martin C; Prevost G; Olivier JP; Dumas F; Duclos B; Olivares R; Leszler A; Bergerat JP; Audhuy B; Thill L; Oberling F
Ann Oncol; 1996 Aug; 7(6):575-9. PubMed ID: 8879370
[TBL] [Abstract][Full Text] [Related]
3. The role of levamisole in the adjuvant treatment of stage III colon cancer patients: a randomized trial of 5-fluorouracil and levamisole versus 5-fluorouracil alone.
Cascinu S; Catalano V; Piga A; Mattioli R; Marcellini M; Pancotti A; Bascioni R; Torresi U; Silva RR; Pieroni V; Giorgi F; Catalano G; Cellerino R
Cancer Invest; 2003; 21(5):701-7. PubMed ID: 14628428
[TBL] [Abstract][Full Text] [Related]
4. A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer.
Piga A; Cascinu S; Latini L; Marcellini M; Bavosi M; Acito L; Bascioni R; Giustini L; Francini G; Pancotti A; Rossi G; Del Papa M; Carle F; Cellerino R
Br J Cancer; 1996 Sep; 74(6):971-4. PubMed ID: 8826868
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
6. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
Ducreux M; Bouche O; Pignon JP; Mousseau M; Raoul JL; Cassan P; Leduc B; Berger C; Dunant A; Fournet J; Bedenne L;
Oncology; 2006; 70(3):222-30. PubMed ID: 16816536
[TBL] [Abstract][Full Text] [Related]
7. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Lee AM; Shi Q; Pavey E; Alberts SR; Sargent DJ; Sinicrope FA; Berenberg JL; Goldberg RM; Diasio RB
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25381393
[TBL] [Abstract][Full Text] [Related]
8. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
Olencki T; Peereboom D; Wood L; Budd GT; Novick A; Finke J; McLain D; Elson P; Bukowski RM
J Cancer Res Clin Oncol; 2001 May; 127(5):319-24. PubMed ID: 11355147
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1.
Staib L; Link KH; Beger HG;
J Gastrointest Surg; 2001; 5(3):275-81. PubMed ID: 11419451
[TBL] [Abstract][Full Text] [Related]
10. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
Ducreux M; Van Cutsem E; Van Laethem JL; Gress TM; Jeziorski K; Rougier P; Wagener T; Anak O; Baron B; Nordlinger B;
Eur J Cancer; 2005 Feb; 41(3):398-403. PubMed ID: 15691639
[TBL] [Abstract][Full Text] [Related]
11. 5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group.
Colucci G; Maiello E; Gebbia V; Giuliani F; Serravezza G; Lelli G; Leo S; Filippelli G; Nicolella G; Brandi M
Cancer; 1999 Feb; 85(3):535-45. PubMed ID: 10091727
[TBL] [Abstract][Full Text] [Related]
12. Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon.
Wadler S; Fell S; Haynes H; Katz HJ; Rozenblit A; Kaleya R; Wiernik PH
Cancer; 1993 Mar; 71(5):1726-30. PubMed ID: 8448736
[TBL] [Abstract][Full Text] [Related]
13. 5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study.
Palmeri S; Gebbia V; Rausa L
J Chemother; 1990 Oct; 2(5):327-30. PubMed ID: 2090772
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.
Fety R; Rolland F; Barberi-Heyob M; Hardouin A; Campion L; Conroy T; Merlin JL; Rivière A; Perrocheau G; Etienne MC; Milano G
Clin Cancer Res; 1998 Sep; 4(9):2039-45. PubMed ID: 9748117
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
[TBL] [Abstract][Full Text] [Related]
16. 5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial.
Tsavaris NB; Tentas K; Kosmidis P; Mylonakis N; Sakelaropoulos N; Kosmas C; Lisaios B; Soumilas A; Mandrekois D; Tsetis A; Klonaris C
Am J Clin Oncol; 1996 Oct; 19(5):517-21. PubMed ID: 8823483
[TBL] [Abstract][Full Text] [Related]
17. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
[TBL] [Abstract][Full Text] [Related]
18. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
Négrier S; Caty A; Lesimple T; Douillard JY; Escudier B; Rossi JF; Viens P; Gomez F
J Clin Oncol; 2000 Dec; 18(24):4009-15. PubMed ID: 11118461
[TBL] [Abstract][Full Text] [Related]
19. Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Zisiadis A; Dafni U; Konstantaras C; Hatzitheoharis G; Papavramidis S; Bousoulegas A; Basdanis G; Giannoulis E; Dokmetzioglou J; Katsohis C; Nenopoulou E; Karvounis N; Briassoulis E; Aravantinos G; Kosmidis P; Skarlos D; Pavlidis N
Oncology; 2000 Apr; 58(3):227-36. PubMed ID: 10765125
[TBL] [Abstract][Full Text] [Related]
20. Fluorouracil and recombinant interferon alfa-2a in advanced gastrointestinal neoplasms.
Pazdur R
Br J Haematol; 1991 Oct; 79 Suppl 1():56-9. PubMed ID: 1931711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
